RG-7410

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.^[1][2] Its route of administration was unspecified.^[1]

RG-7410

Clinical data
Other names	RG7410
Routes of administration	Unspecified[1]
Drug class	Trace amine-associated receptor 1 (TAAR1) agonist[1]
Identifiers
CAS Number	1967845-81-3

The drug reached phase 1 clinical trials prior to the discontinuation of its development.^[1][2] It was under development by Hoffmann-La Roche.^[1][2] RG-7410 was first disclosed by January 2014^[3] and a phase 1 trial was reported to have been completed by October 2014.^[4]

See also

• Ralmitaront (RG-7906; RO-6889450)
• RG-7351
• Ulotaront (SEP-363856; SEP-856)